Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TherapeuticsMD Inc (TXMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TXMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $5
Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.86% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.43M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.64 | 52 Weeks Range 0.70 - 1.95 | Updated Date 07/1/2025 |
52 Weeks Range 0.70 - 1.95 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -114.07% | Operating Margin (TTM) -199.24% |
Management Effectiveness
Return on Assets (TTM) -4.88% | Return on Equity (TTM) -7.72% |
Valuation
Trailing PE - | Forward PE 2.29 | Enterprise Value 14652259 | Price to Sales(TTM) 7.29 |
Enterprise Value 14652259 | Price to Sales(TTM) 7.29 | ||
Enterprise Value to Revenue 7.96 | Enterprise Value to EBITDA 14.81 | Shares Outstanding 11574400 | Shares Floating 9560770 |
Shares Outstanding 11574400 | Shares Floating 9560770 | ||
Percent Insiders 2.08 | Percent Institutions 44.06 |
Analyst Ratings
Rating 1 | Target Price 5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TherapeuticsMD Inc
Company Overview
History and Background
TherapeuticsMD Inc. was founded in 2008 and focused on developing and commercializing products targeted exclusively for women. Initially, the company aimed to address unmet needs in women's health through hormone therapy and related products.
Core Business Areas
- Hormone Therapy Products: Development and commercialization of hormone therapy products for menopausal symptoms.
Leadership and Structure
TherapeuticsMD's leadership included key executives overseeing research and development, commercial operations, and finance. The organizational structure involved departments focused on product development, regulatory affairs, sales, and marketing.
Top Products and Market Share
Key Offerings
- Bijuva: Bijuva is a bio-identical hormone therapy combining estradiol and progesterone in a single capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. Competitors include other hormone therapy options such as those from Mylan (now Viatris) and Pfizer.
- Imvexxy: Imvexxy is a low-dose vaginal estrogen product used to treat moderate to severe dyspareunia (painful sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause. Competitors include products such as Vagifem.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the women's health segment, is competitive, with companies developing and marketing various hormone therapies and related products. The market is driven by the aging population and increasing awareness of women's health issues.
Positioning
TherapeuticsMD aimed to carve out a niche in the women's health market by focusing on bio-identical hormone therapies. However, the company faced challenges in gaining significant market share due to competition from established players.
Total Addressable Market (TAM)
The global hormone replacement therapy market was valued at approximately $16.9 billion in 2023. TherapeuticsMD was positioned to capture a portion of this TAM, but was ultimately unsuccessful.
Upturn SWOT Analysis
Strengths
- Focus on bio-identical hormone therapies
- Portfolio of approved products
Weaknesses
- Limited market share
- Dependence on a narrow product line
- Heavy debt burden
Opportunities
- Expanding product portfolio
- Acquisition/Merger opportunities
Threats
- Competition from established pharmaceutical companies
- Regulatory changes
- Generic entry of key products
Competitors and Market Share
Key Competitors
- VTRS
- PFE
Competitive Landscape
TherapeuticsMD faced stiff competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. The company's limited market share and financial constraints hindered its ability to compete effectively.
Major Acquisitions
VitaCare Prescription Services
- Year: 2020
- Acquisition Price (USD millions): 39
- Strategic Rationale: The acquisition aimed to improve patient access to TherapeuticsMD's products.
Growth Trajectory and Initiatives
Historical Growth: TherapeuticsMD experienced some growth in revenue, but it was insufficient to offset its expenses and debt.
Future Projections: Given the current state of the company following its delisting and strategic alternatives review, future projections are not applicable.
Recent Initiatives: The company underwent a strategic alternatives review and reverse stock split in an effort to remain viable. They were bought out by EW Healthcare Partners.
Summary
TherapeuticsMD was a company focused on women's health with a portfolio of approved products, but faced substantial financial challenges. High debt, significant operating expenses, and intense competition hindered its growth and profitability. The company's strategic initiatives and acquisition strategies were not enough to overcome these hurdles, leading to its acquisition by EW Healthcare Partners. The company was fundamentally weak and required significant restructuring to survive in the long term.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market reports
- Financial news sources
Disclaimers:
The information provided is based on available data and analysis, and may be subject to change. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TherapeuticsMD Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2003-12-11 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1 | Website https://www.therapeuticsmd.com |
Full time employees 1 | Website https://www.therapeuticsmd.com | ||
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.